TNFi and RA-ILD – The Pendulum Swings Again Tumour necrosis factor inhibitors (TNFi) revolutionised the treatment of rheumatoid arthritis. They heralded the wave of advanced therapies, which has transformed the treatment landscape in rheumatic disease. https://t.co/zBwJKyDihL https://t.co/uCLnmaLC9j

#ACR23 Abst#1629 from FORWARD registry showed RA pts (n667) with LONG COVID (15%) had worse RA pre-COVID and post-infx, and had worse COVID (more ABx & hospitalization). RA-long Covid pts had 3fold more fibromyalgia (13 vs 41%) https://t.co/VFNAnSxNzN https://t.co/WLqmdM3Nn2

Watch: No Increased Mortality in Patients with RA Receiving Checkpoint Inhibitors Dr. Mike Putman discusses abstract 1071 with Dr. Madeline O'Sullivan at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/YdIlhLf5gh https://t.co/6dfWHakboh

ACR Daily Recap - MONDAY Panelists: Drs. Kathryn Dao, Michael Putman and Eric Dein Moderator: Dr. Jack Cush https://t.co/b1k1gsHI2z https://t.co/BWu7GXFxhj

IgG4 disease- the WInS withdrawal study results https://t.co/rg0YJ0LlZM https://t.co/L6SzcD7QlJ

Theres a ustekinumab biosimilar, CT-P43 - In a multinational, phase III study in 509 plaque psoriasis pts, CT-P43 was equivalent to the originator, Stelara, with week 16 PASI75 scores of 78% vs 76%, and continued efficacy out to week 40 https://t.co/dEImEp8l90 https://t.co/UoqGgaad8H

FDA issued a safety alert for BCMA- or CD19- Autologous CAR-T cell Immunotherapies; they've received reports & are investigating Risk of T-cell Malignancy (CAR-positive lymphoma) occuring in several products w/in this class (most for Cancer use) https://t.co/RpBhcGarGy https://t.co/mDuXmVW4Fz

Rheumatoid Arthritis Topic Podcast https://t.co/ClEuz2bVzA https://t.co/19jZhSt3Dc

Does GnRHa Reduce Premature Ovarian Insufficiency in SLE Patients on Cyclophosphamide? https://t.co/GVk2KLoGYq https://t.co/Hv9Bcn8cLg

Why are older RA patients getting mistreated? Most rheums would say that every RA patient should be started on a DMARD. So I'm shocked that, in a US Medicare 20% sample dataset b/w 2008-17, less than 30% of new RA patients aged 66+ have a DMARD initiated. https://t.co/VFp3oz8wGK https://t.co/60Jn6ShmDs

Do We Stop or Continue Treatment? Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life. https://t.co/qSgfuDvAQb https://t.co/eUzIaC35tl